Ethical Matters Regarding Fertility Preservation Strategies in the World of Assisted Reproductive Medicine

2020 ◽  
Vol 3 (1) ◽  
pp. 77-81
Author(s):  
Adina-Elena Tănase ◽  
◽  
Mircea Onofriescu ◽  
◽  
Author(s):  
Elena Vladimirovna Frolova

In terms of its efficiency and accessibility, the health care of Cyprus is not inferior in many ways to the systems of medical care in a number of developed countries of the world. By placing the main emphasis on the organization of preventive care, the Cypriots were able to achieve quite a high level of life expectancy — 85 years for women and 81 years for men. Due to its excellent geographical position and mild climate, the country has a special attraction in terms of medical tourism, the most popular areas of which are plastic cosmetology, dentistry, and reproductive medicine. Foreigners who come for medical services have the opportunity not only to improve their health, but also to have a wonderful rest, enjoy Mediterranean cuisine, golden sandy beaches and blessed sunshine. Fortunately, nature provides all the opportunities for this — scientists say that at least 300 days a year are sunny on this island.


2018 ◽  
Vol 79 (01) ◽  
pp. 53-62 ◽  
Author(s):  
Matthias Beckmann ◽  
Laura Lotz ◽  
Bettina Toth ◽  
Dunja Baston-Büst ◽  
Tanja Fehm ◽  
...  

AbstractThe cryopreservation of ovarian tissue with subsequent transplantation of the tissue represents an established method of fertility protection for female patients who have to undergo gonadotoxic therapy. The procedure can be performed at any point in the cycle and thus generally does not lead to any delay in oncological therapy. With the aid of this procedure, more than 130 births to date worldwide have been able to be recorded. The birth rate is currently approximately 30% and it can be assumed that this will increase through the further optimisation of the cryopreservation and surgical technique. The concept paper presented here is intended to provide guidance for managing cryopreservation and transplantation of ovarian tissue to German-speaking reproductive medicine centres.


2020 ◽  
Vol 105 (10) ◽  
pp. 3335-3345
Author(s):  
Allison C Mayhew ◽  
Veronica Gomez-Lobo

Abstract Comprehensive care for transgender and gender nonbinary patients has been a priority established by the World Professional Association for Transgender Health. Because pubertal suppression, gender-affirming hormone therapy, and antiandrogen therapy used alone or in combination during medical transition can affect gonadal function, understanding the effects these treatments have on fertility potential is important for practitioners caring for transgender and gender nonbinary patients. In this review, we outline the impacts of gender-affirming treatments on fertility potential and discuss the counseling and the treatment approach for fertility preservation and/or family building in transgender and gender nonbinary individuals.


Reproduction ◽  
2015 ◽  
Vol 150 (3) ◽  
pp. S1-S10 ◽  
Author(s):  
Teresa K Woodruff

In 2007, I was asked by the University of Calgary to participate in a symposium called ‘Pushing the Boundaries – Advances that Will Change the World in 20 Years’. My topic was oncofertility, a word I had just coined to describe the intersection of two disciplines – oncology and fertility – and I was thrilled to share my passion for this new field and help young women with cancer protect their future reproductive health. Fertility preservation in the cancer setting lacked a concerted effort to bridge the disciplines in an organized manner. In early 2015, I was delighted to deliver a presentation for the Society for Reproduction and Fertility titled ‘Sex in Three Cities’, where I gave an update on the oncofertility movement, a remarkable cross-disciplinary, global collaboration created to address the fertility preservation needs of young cancer patients. During my tour of the UK, I was impressed by the interest among the society and its members to engage colleagues outside the discipline as well as the public in a dialogue about cutting-edge reproductive science. In this invited review, I will describe the work of the Oncofertility Consortium to provide fertility preservation options in the cancer setting and accelerate the acceptance of this critical topic on a global scale. I hope that one day this word and field it created will change the world for women who had been left out of the equation for far too long.


Lupus ◽  
2010 ◽  
Vol 19 (4) ◽  
pp. 446-452 ◽  
Author(s):  
DW Branch ◽  
RM Silver ◽  
TF Porter

The subject of obstetric antiphospholipid syndrome (APS) has been reviewed dozens of times, and there is little doubt that the international APS community has done well in bringing APS to the attention of clinicians around the world. However, the evolution of clinical practice, at least in the US, also has convinced us that our field would benefit from further clinical study. For example, the number of women diagnosed with ‘APS’, but who do not meet the revised Sapporo criteria, seems to have increased. It is now common practice for women with recurrent miscarriage or prior fetal death to be treated with heparin, even in the presence of indeterminate or low titer antiphospholipid antibody (aPL) levels and even after only one positive test. In part, this common practice derives from confusion on the part of many clinicians and patients regarding the diagnosis of APS as well as the clinical and laboratory criteria for the syndrome. In part, this derives from the common practice of so-called ‘empiric treatment’ in US reproductive medicine, often driven as much by patients as by clinicians. This brief commentary focuses on areas of uncertainty that we see as deserving of new or renewed study for the sake of improving our understanding of APS and best patient care.


2020 ◽  
Vol 13 (4) ◽  
pp. 416-420 ◽  
Author(s):  
Bettina Böttcher ◽  
Katharina Winkler-Crepaz

SummaryFertility preservation in women has become well established over the last two decades. Nevertheless, options for cancer survivors need to be improved to regain ovarian functioning, ideally leading to pregnancy and live birth. Techniques to protect the ovary from the damage of cytotoxic agents, to improve the survival of follicles in the ovarian graft, and to minimize the risk of re-seeding malignant cells after ovarian tissue transplantation are the object of current research all over the world. The demand for fertility preservation procedures in patients with benign diseases like systemic lupus erythematosus before cytotoxic therapy, in patients with endometriosis before surgery, and in patients with genetic predispositions which can lead to a premature ovarian failure will further increase in coming years. In this short review, these future perspectives are presented.


2016 ◽  
Vol 85 (4) ◽  
pp. 237-244
Author(s):  
P. E. J. Bols ◽  
H. F. M. De porte

There was a time when science still had to ‘hatch’. An era during which man often extrapolated existing knowledge to a level beyond reality. That period is not as far behind us as we would like to believe. Breeding of animals has always stimulated man’s fantasy. Out of this, a very interesting myth - or is it a mystery? - was born: the existence of a hybrid between horse and cow, ‘Le Jumart’. On top of the very well-known hybrids between horses and donkeys, the French ‘capitaine des haras’ Francois Alexandre de Garsault (1692-1778) describes the procedure of how to create a hybrid between a cow and a horse in his widespread and well known ‘Nouveau Parfait Maréchal’, first published in 1741. In depth research showed that he was far from being the only one who believed in the existence of such a crossover species. Other well-respected contemporary scientists even dedicate chapters in their textbooks on this animal, such as the French naturalist and medical doctor Jean-Pierre Buchoz (1731-1807) in his ‘Traité Economique et Physique de Gros Menu Bétail’ published in 1778. Even opinion leaders Charles Bonnet (1720-1793) and Lazzarro Spallanzani (1729-99) were convinced that these animals really roamed around in France during the 18th century. Finally, even the founder of the first ‘Ecole Vétérinaire’ in the world, Claude Bourgelat (1712-1779) testified in a letter to Bonnet to have admired the product of a stallion and a cow with his own eyes. Fortunately, the debate could count on important disbelievers as well, with Albrecht von Haller taking the lead by publishing a paper in the ‘Supplément à l’Encyclopédie ou Dictionnaire Raisonné des Sciences, des Arts et Métiers’ (1777), in which he calls the existence of the Jumart a ‘fable’. It would take another century for André Suchetet (1849-1910) to publish an ‘Extrait des Mémoires de la Société Zoologique de France’ with the title ‘La Fable des Jumarts’ (1889). Extremely interested in hybridization, this 19th century politician and member of several scientific societies, faces the challenge to finally steer the scientific community to a general conclusion on this enigma. This paper describes in a chronological order the rise and fall of one of the most intriguing ‘fabula’ in reproductive medicine and how it took emerging modern science about 200 years to decide on ‘myth’ or ‘mystery’.


Sign in / Sign up

Export Citation Format

Share Document